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Abstract. Toxoplasma gondii is a leading cause of severe foodborne illness in the United States. Population-based
studies have found T. gondii infection to be more prevalent in racial/ethnic minority and socioeconomically dis-
advantaged groups. Soil contaminated with cat feces, undercooked meat, and congenital transmission are the principal
sources of infection. Toxoplasmosis-associated illnesses include congenital neurologic and ocular disease; acquired illness
in immunocompetent persons, most notably ocular disease; and encephalitis or disseminated disease in immunosuppressed
persons. The association of T. gondii infection with risk for mental illness is intriguing and requires further research.
Reduction of T. gondii in meat, improvements in hygiene and food preparation practices, and reduction of environ-
mental contamination can prevent toxoplasmosis, but more research is needed on how to implement these measures.
In addition, screening and treatment may help prevent toxoplasmosis or reduce the severity of disease in some settings.
INTRODUCTION
Toxoplasmosis is an infection caused by the protozoan par-
asite Toxoplasma gondii. Cats are the definitive host in which
the organism can complete its sexual cycle. Cats usually shed
the environmentally resistant oocyst form of the organism in
their feces for 1–2 weeks after a new infection, although in
specific situations related to strain types, co-infection with
Cystoisospora felis (syn. Isospora felis), and immunosuppres-
sion, repeat shedding is possible.1 Sporulation is required for
oocysts to become infectious and occurs within 1–5 days in
the environment. Sporulated oocysts are quite hardy; they
can remain infective in a moist environment for a year or
more.1 Once ingested by humans or any other warm-blooded
animal, the parasite transforms into a tissue-infective stage
in the intestine, migrates through the intestinal wall, and is
carried via the blood to other tissues including the central
nervous system.
Humans are accidental hosts and can be infected through a
variety of exposures. Food-borne transmission occurs with
ingestion of raw or undercooked meat containing the parasite
in tissue cysts (usually pork, lamb, goat, or wild game meat,
although beef and field-raised chickens have been implicated
in epidemiologic studies),2 or through ingestion of food, soil,
or water contaminated by cat feces (for example, from eating
unwashed fruits and vegetables, gardening, or cleaning a cat’s
litter box). Mother-to-child transmission typically occurs when
a pregnant woman is newly infected during, or just prior to,
her pregnancy. The organism can also be transmitted when
a previously uninfected person receives an organ or blood
transfusion from an infected donor.
The proportion of human T. gondii infections acquired by
eating meat containing infective cysts versus ingesting oocysts
from cat feces contamination is not known for a representa-
tive sample of the general population. However, ingestion of
oocysts from cat feces/soil and ingestion of tissue cysts in meat
both are significant contributors to the disease burden in
humans, although oocysts have recently been shown to play
an important role.3–5 Modern confinement production has
decreased T. gondii contamination of meat but there is concern
that a new trend in the production of free-range raised animals
for meat could increase the risk of contamination.2
Three principal clonal T. gondii genotypes were originally
detected, primarily in isolates from the United States and
Europe. However, more recently using sequence-based tech-
nology 15 haplogroups that define 6 major clades have been
described,6 and the new paradigm is that many atypical geno-
types differ in pathogenicity and transmissibility from typical
genotypes.7 Research supports the concept that T. gondii
genotype may be related to disease severity.8–10 However,
there is relatively little information about T. gondii genotypes
infecting asymptomatic persons, and in general, the clinical
implications of T. gondii strains are incompletely understood.
CLINICAL MANIFESTATIONS
A self-limited or mild illness characterized by fever, malaise
and lymphadenopathy is often seen after T. gondii infection,
but many infections are subclinical. However, regardless of
initial symptoms, a chronic infection is established, and
immunosuppression, such as occurs with advanced human
immunodeficiency virus disease or use of immunosuppressive
medications in cancer treatment or after organ transplant,
can result in disease reactivation and severe morbidity
including neurologic involvement, or mortality. In those with
advanced human immunodeficiency virus–related immuno-
suppression, encephalitis is a common manifestation unless
long-term prophylactic medication is taken.
Congenital infection can cause pregnancy loss (miscarriage
or stillbirth) or severe disease in the newborn, including
developmental delays, blindness, and epilepsy.11 However,
many newborns with congenital toxoplasmosis are asymptom-
atic at birth. Nevertheless, even if asymptomatic at birth, ill-
ness will develop in many infected infants later in their life,
most often ocular disease, but also neurologic symptoms and
developmental disabilities.11 For example, 82% of congeni-
tally infected children (9 of 11, including 4 who received treat-
ment) were shown to have ocular lesions by age 20 in one
small prospective series.12 Other studies confirm the risk for
severe illness among congenitally infected children but have
found a somewhat lower risk in treated children. For example,
in a group of 127 treated children followed-up to 16 years in
France, ocular lesions were present in 18.9%.13 In another
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series of 130 treated children followed-up 12 years in France,
ocular involvement was found in 30%,14 and in a third series
of French adults (median age = 22 years) who had congenital
toxoplasmosis that was treated pre- and post-natally, 59% had
ocular lesions but only 13% had reduced vision.15 A compar-
ison of cohorts of children with congenital toxoplasmosis in
Brazil with those in Europe found that T. gondii causes more
severe ocular disease in congenitally infected children in
Brazil.9 The authors suggested that the increased frequency
and severity of ocular disease in Brazil compared with that in
Europe may be caused by more virulent type 1 and atypical
strains found there.9 In general, infants born to women who
were infected with T. gondii more than a few weeks before
conception are not at risk for congenital infection, although
congenital infection from women with chronic T. gondii infec-
tion has occurred with reactivation in immunosuppression or
with infection by atypical genotypes.7
Although T. gondii infection appears to be lifelong, for
most healthy persons infected outside of infancy it has long
been believed that further clinical manifestations after acute
infection are rare. However, studies have now revealed asso-
ciations between T. gondii antibody seropositivity (indicating
infection) and the presence of various psychiatric disorders
in humans (e.g., schizophrenia,16 bipolar illness,17 suicide
attempts,18 episodes of self-directed violence,19 and memory
impairment in elderly persons20). Although these results
are intriguing and potentially signal a new and compelling
reason to redouble efforts to prevent toxoplasmosis, addi-
tional studies are needed to fully elucidate the relationship
between T. gondii infection and mental illness, and how the
strain and stage of T. gondii (oocyst versus tissue cyst) affects
this relationship.21
DIAGNOSIS AND TREATMENT
Toxoplasma gondii infection can be diagnosed by testing
for antibodies against Toxoplasma, as well as by direct test-
ing or visualization of the parasite in body tissues or fluids.
Basic antibody tests (e.g., IgG and IgM) are available com-
mercially. Detection of IgG against Toxoplasma indicates
previous exposure, but does not indicate when infection
occurred. Detection of IgM against Toxoplasma is sugges-
tive of acute infection, but IgM can persist for months or
even years after infection and false-positive IgM test results
can occur in persons who are chronically infected or not
infected with T. gondii.22 Therefore, when clinical action
depends on test results, IgM test results should be verified
at a reference laboratory, especially for pregnant women
and newborns.23 Antibody avidity testing can been used to
help distinguish between recent and distant infection,24 an
important consideration for pregnant women when IgM is
detected and the risk for congenital toxoplasmosis is being
assessed. Avidity testing is available in many countries
including the United States.25
Treatment recommendations vary with the type and sever-
ity of infection. Mild disease in adults with normally func-
tioning immune systems rarely requires treatment, whereas
severe disease, including disease in immunosuppressed per-
sons, requires treatment with a combination of anti-parasitic
medications (e.g., pyrimethamine and sulfadiazine).26,27 Clini-
cal management of pregnant women and infants with congeni-
tal infection is complex and consultation with a specialist
is advised.28
PUBLIC HEALTH SIGNIFICANCE
OF TOXOPLASMOSIS IN THE UNITED STATES
Toxoplasmosis is responsible for considerable morbidity
and mortality in the United States. Serologic evidence of
infection is more frequently seen in black and Hispanic per-
sons, and among persons who are foreign-born, have low edu-
cational levels or socioeconomic status, or have occupations
involving exposure to soil.29,30 Serologic evidence of Toxocara
(dog or cat roundworm) infection, which is soil-borne, is more
commonly seen among those with T. gondii infection, suggest-
ing common risk factors for acquiring the two infections.31
In the United States, studies examining data from the
mid to late 2000s estimated toxoplasmosis to be the second
leading cause of deaths attributable to foodborne illness
(an estimated 327 deaths), the fourth leading cause of hos-
pitalizations attributable to foodborne illness (an estimated
4,428 hospitalizations), and a leading contributor to loss of
quality-adjusted life years.32,33 Toxoplasma gondii infects
an estimated 1.1 million persons each year in the United
States.34 Chorioretinitis caused by infection with T. gondii
develops in an estimated 21,000 persons each year, and symp-
tomatic chorioretinitis, leading to vision loss, develops in more
than 4,800 of these persons.34 Because symptoms in the eye
recur over time and new lesions commonly develop, these
calculations are likely to be minimum estimations of the inci-
dence of symptomatic ocular toxoplasmosis. Ocular toxoplas-
mosis creates a significant burden on the healthcare system,
with an estimated 250,000 visits to ophthalmologists for active
or chronic disease over a two-year period.35
Serologic surveys over past decades indicate that rates of
infection with T. gondii have decreased in the United States.
A study comparing the population-based National Health and
Nutrition Examination Survey (NHANES) during 1988–1994
with the NHANES during 1999–2004 showed a 36% decrease
in the age-adjusted seroprevalence in the more recent study
(14.1% to 9.0% in persons 12–49 years of age).30 Preliminary
results from the NHANES 2009–2010 show further decreases
(Jones J, unpublished data). Because in the older study
(NHANES 1988–1994) all persons ³ 12 years of age were
tested, an estimate could be made for the overall population
in this age range. The age-adjusted T. gondii antibody sero-
prevalence was 22.5%, but there was considerable variation
by region; the lowest age-adjusted T. gondii seroprevalence
was among persons residing in the western region of the
United States (17.5%) and highest in the North-
east (29.2%).29
An estimated 400–4,000 infants are born with congenital
toxoplasmosis each year in the United States.36–38 Overall,
approximately 30% of women who acquire infection during
pregnancy transmit the infection to the fetus; the risk of
transmission from mother to child is lowest when infection
occurs during the first trimester (10–15%) and higher as
pregnancy progresses to the third trimester (60–90%).39
However, injury to the fetus is usually greatest when acute
infection occurs early in pregnancy,39 although some atypical
genotypes can cause severe congenital toxoplasmosis in the
third trimester.7
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Estimates of the incidence of congenital infections vary in
the United States. The most recently published population-
based estimate is derived from the New England Newborn
Screening program in the late 1980s and early 1990s,38,40
a region shown to have the highest prevalence of T. gondii
infection in the United States.29 Analysis of newborn IgM
blood spot screening tests in Massachusetts and New
Hampshire yielded an estimate of 1 case per 12,212 live
births.40 More recent data from the New England Newborn
Screening Program showed that congenital toxoplasmosis
rates during 2000–2010 ranged from approximately 1.3 to
6.8 per 100,000 live births (Eaton R, unpublished data).
Newborn screening filter paper blood spot IgM test sensitiv-
ity is low (approximately 50–75%).41–43 In addition, because
false-positive IgM test results also occur, serum samples from
the mother and infant must be followed-up to verify true
positive test results.40 Older local studies in the United States
found congenital toxoplasmosis rates of approximately 1 per
1,000 newborns.44,45 Similar to seroprevalence estimates
among adults, rates of congenital infection are likely to vary
by region of the United States.
PREVENTION STRATEGIES
The devastating impact of congenital infection has led to
great interest in reducing risk through screening. In one eco-
nomic analysis, an approach comprised of monthly prenatal
T. gondii screening and treatment of women infected in preg-
nancy coupled with one year of treatment of infected new-
borns with pyrimethamine and sulfonamides was estimated
to be cost saving if the rate of congenital infection was
greater than 1 per 10,000 live births.46 However, the cost
savings were based on an ideal program with all prenatal
visits conducted on time, all tests validated at a highly
expert reference laboratory, and when required, treatment
given soon after maternal seroconversion. The efficacy of
treatment of pregnant women and infants has not been
determined by well-controlled randomized trials, either for
the ability to prevent congenital infection or reduce sequlae
in infected infants. Treatment is thought to be most effec-
tive if given within days to weeks of seroconversion in preg-
nant women. Even in France, where routine screening has
been recommended for decades, a study found late initial
testing and poor compliance with recommended screening
intervals (the first test was performed later than the recom-
mended first 12 weeks of pregnancy in 25% of women, and
only 40% of women had the recommended number of
screening tests in pregnancy).47 In Austria, where prenatal
screening every trimester has been recommended and con-
ducted for three decades, only 30% of seronegative women
were found to be tested at least three times during their
pregnancies.48 These findings imply that in a real-world
setting it can be challenging to screen and treat newly sero-
converted pregnant women soon after infection. Neverthe-
less, the societal and economic costs of care for developmental
disabilities such as congenital toxoplasmosis, estimated to
be from approximately 500,000 to 3.3 million U.S. dollars
per case according to the severity,46 are considerable for
symptomatic cases.
Although there has been some enthusiasm within the
medical community for prenatal or neonatal screening
programs, others, including the United Kingdom National
Screening Committee, have argued that there is currently no
evidence from randomized placebo-controlled trials demon-
strating efficacy for screening and treatment of congenital
toxoplasmosis.49–51 In recent years, prenatal or neonatal toxo-
plasmosis screening has been evaluated but not adopted in
numerous countries in Europe, including the United Kingdom,
Switzerland, and Denmark50–53; and in Canada and Israel.54,55
Screening in these countries was not adopted because of a
low incidence of T. gondii infection (similar to that of the
United States), concerns about the lack of well-controlled
studies documenting benefit, and concerns about potential
costs and harms of the programs outweighing benefits in a
practical setting. In addition, the American College of
Obstetricians and Gynecologists did not recommend univer-
sal screening of pregnant women for T. gondii infection in
their practice guidelines.56 Studies and systematic reviews
have yielded conflicting results on the benefits of prenatal
screening and treatment of congenital toxoplasmosis.57–66
There is a need for well controlled studies to help determine
the effectiveness these interventions.
Preventing infection of pregnant women through educa-
tion is another potentially beneficial strategy. A study of
pregnant women in the United States found that they often
lack knowledge about how to prevent T. gondii infection,
especially the risks associated with eating or handling raw
or undercooked meat.67 Although numerous studies have
provided some evidence that education of pregnant women
may be beneficial,68–72 one review of toxoplasmosis-related
health education called for more rigorously designed research
on prevention of toxoplasmosis through education, and
questioned the validity of results from published studies.73
In addition, a recent Cochrane systematic review found very
little rigorous scientific evidence that prenatal education is
effective in reducing congenital toxoplasmosis and called for
randomized controlled trials to confirm the potential benefits
and quantify the impact of educational interventions.74
Vaccination of cats for toxoplasmosis has also been pro-
posed as a control method and an oral live vaccine prevented
cats from shedding oocysts in clinical trials.75 However, the
commercial production of toxoplasmosis vaccine for cats
was discontinued because of its high cost, the need to keep
the vaccine frozen, its short shelf life, and lack of interest
among cat owners.1 A live toxoplasmosis vaccine for sheep
that produces protective immunity for 18 months is avail-
able in some countries (but not in the United States) to
reduce loss of lambs.76 Vaccination with killed T. gondii
preparations has been unsuccessful. For humans, develop-
ment of a live mutant or avirulent strain vaccine has not
been pursued because these strains may pose a risk to the
fetus and there is insufficient data on the risk of reversion
to T. gondii strains that could cause disease, particularly in
immunosuppressed persons.
GAPS IN CURRENT KNOWLEDGE
AND PROGRAMATIC INTERVENTIONS
Despite limited data on the incidence and prevalence of
infection and illness caused by T. gondii, toxoplasmosis is
clearly an important public health problem in the United
States and globally. Much remains to be learned about toxo-
plasmosis to improve our knowledge of the disease, as well as
to decrease infection rates through prevention and treatment.
796 JONES AND OTHERS
Further insight into the number of children infected by
mother-to-child transmission could be gained by conducting
a pilot prenatal screening and treatment program with active
surveillance for congenital toxoplasmosis. However, the ben-
efits of treatment remain uncertain and treatment trials with
placebo treatment groups might be problematic from an
ethical standpoint. In addition, because the congenital toxo-
plasmosis rate is low in the United States, appropriately
controlled studies of treatment efficacy would require mil-
lions of study participants and be extremely expensive.
Given these limitations, a monitored pilot evaluation of pre-
natal screening and treatment in a high-risk country or geo-
graphic region may be the best practical option, even if only
a subset of the population undergoing prenatal screening is
monitored for outcomes (e.g., randomly selected healthcare
facilities, or sentinel sites).
There are numerous potential T. gondii maternal screening
program pitfalls that include: lack of confirmation of positive
screening test results before taking clinical actions, such as
amniocentesis to assess fetal infection or implementing
treatment; risk of amniocentesis to verify fetal infection;77,78
and late initial testing and poor compliance with screening
intervals that lead to delayed initiation of therapy, as has been
a problem in France and Austria.47,48,79 Because routine
prenatal T. gondii infection screening would be new in low-
incidence countries such as the United States, and the practi-
calities of its implementation in such countries are unknown,
assessments of such screening and treatment programs should
include 1) the proportion of T. gondii testing in pregnancy
performed at correct intervals, and 2) the appropriate use of
reference laboratories to validate test results, 3) evaluation of
elective pregnancy terminations in women who show positive
test results but who have not had their tests results confirmed,
4) the outcome and side effects of amniocentesis used to
verify fetal infection, 5) the side effects of medications used
in pregnant women and infants, 6) the time after maternal
seroconversion that treatment is initiated, 7) the regimen used
for treatment, 8) patient compliance with the treatment,
9) the outcome in infants, and 10) the costs and benefits. In
the United States, if large numbers of tests were performed for
screening, it is not certain that confirmatory testing could be
limited to one expert reference laboratory, or even to several
commercial laboratories, and in the past T. gondii tests at some
commercial laboratories have not been accurate.22
The diagnosis of toxoplasmosis can be difficult, especially
in immunosuppressed patients and in persons with congenital
disease. Diagnostic tools for toxoplasmosis, including poly-
merase chain reaction, more sensitive and specific IgM tests,
Western blots for comparison of maternal and infant antibody
response, and strain typing tests, would benefit from further
development.11,80–82 In addition, relatively little is known
regarding treatment efficacy for ocular disease.83,84 Improve-
ments in treatment could potentially be achieved through
1) trials to establish the efficacy for preventing congenital
transmission and sequlae in infants, as well as the optimal
medications and duration of therapy; and 2) collaboration
with those in the ophthalmologic community to improve detec-
tion and treatment of ocular disease and to create standard-
ized, evidence-based practices for ocular disease designed to
minimize morbidity and to prevent recurrent disease.
The reduction in prevalence of T. gondii infection in the
United States suggests that efforts to improve quality control
by meat producers and improved cat-care hygiene, as well
as efforts to increase knowledge about toxoplasmosis among
physicians and the public, have been successful in reducing
toxoplasmosis risk.30 Further reductions in infection could be
achieved through identification and mitigation of risk factors
for T. gondii infection, including 1) encouraging good produc-
tion practices by meat producers, 2) developing methods
to minimize environmental contamination of soil and water
with T. gondii, and 3) improving patient education and public
health messages to reduce ingestion of undercooked meat
and improve cat feces–related and soil-related hygiene.67,85,86
Further understanding of the impact of toxoplasmosis on
health, including mental health, is needed to help keep public
health resources focused on prevention efforts. Continued
evaluation of T. gondii infection using population-based stud-
ies to monitor the prevalence and temporal trends in infection
will be essential to measure the impact of prevention efforts
and guide adjustments in prevention strategies.
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